WO2006062097A1 - 掻痒の治療及び/又は予防剤 - Google Patents
掻痒の治療及び/又は予防剤 Download PDFInfo
- Publication number
- WO2006062097A1 WO2006062097A1 PCT/JP2005/022372 JP2005022372W WO2006062097A1 WO 2006062097 A1 WO2006062097 A1 WO 2006062097A1 JP 2005022372 W JP2005022372 W JP 2005022372W WO 2006062097 A1 WO2006062097 A1 WO 2006062097A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- alkyl
- phenol
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Definitions
- the present invention relates to a pharmaceutical for treatment and Z or prevention of epilepsy comprising a pyrazolone derivative or a physiologically acceptable salt thereof, or a hydrate or solvate thereof as an active ingredient.
- Acupuncture is an unpleasant sensation that makes you want to scratch or rub the skin, and is one of the important symptoms in many skin diseases.
- many skin diseases accompanied by hemorrhoids the patient suffers from the bruising of the affected area (also referred to as breaching behavior), which causes problems such as worsening of symptoms and chronicity.
- neuropeptides such as histamine, bragicun, and substance P, proteolytic enzymes, prostaglandins, platelet activation factor, leukotriene B4, lymphokine and the like are known.
- antihistamines, antiallergic agents, steroids, moisturizers and the like are known as drugs for suppressing wrinkles of atopic dermatitis.
- nitric oxide synthase N-oxide
- JP 2002-138052 describes an acupuncture drug containing as an active ingredient a compound that selectively inhibits neuronal nitric oxide synthase (nNOS)! Speak.
- ion channel glutamate receptors are available in NMDA, ⁇ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ( ⁇ ), and kainate types. Forces to be classified These receptors are distributed not only in the central nervous system but also in the sensory nerve endings of the skin in humans, and are implicated in the transmission of pain (noxious stimuli), for example.
- Japanese Patent Application Laid-Open No. 2003-81872 describes an acupuncture drug containing as an active ingredient a compound that selectively inhibits a glutamate receptor.
- R 1 represents a hydrogen atom, aryl, alkyl having 1 to 5 carbon atoms, or an alkoxycarboxylic alkyl having 3 to 6 carbon atoms in total
- R 2 represents a hydrogen atom, aryloxy, aryl carbonate, carbon number 1 to 5 represents alkyl of 1 to 3 or hydroxyalkyl of 1 to 3, or R 1 and R 2 together represent alkylene of 3 to 5 carbon atoms
- R 3 represents a hydrogen atom, alkyl of 1 to 5 carbon atoms, Cycloalkyl having 5 to 7 carbon atoms, hydroxyalkyl having 1 to 3 carbon atoms, benzyl, naphthyl or phenyl, or alkoxy having 1 to 5 carbon atoms, hydroxyalkyl having 1 to 3 carbon atoms, total carbon number 2 to 5 alkoxy carbonyl, 1 to 3 alkyl mercapto, 1 to 4 alkyl amide-containing total alkyl 2 to 8 dialkyl amide
- edaravone is a free radical force venger that works to prevent cell damage by scavenging various free radicals including active oxygen.
- edaravone is effective for the treatment and Z or prevention of acupuncture. Disclosure of the invention
- An object of the present invention is to provide a medicament useful for treatment and Z or prevention of epilepsy.
- An object of the present invention is to provide the above medicament having a mechanism other than the antihistamine action.
- the present inventors examined the therapeutic effect on epilepsy using a pyrazolone derivative represented by the formula (I). As a result, it was found that administration of the above-described pyrazolone derivative can suppress wrinkles, and the present invention has been completed.
- R 1 represents a hydrogen atom, an aryl group, an alkyl group having 1 to 5 carbon atoms or an alkoxycarboalkyl group having 3 to 6 carbon atoms in total
- R 2 represents a hydrogen atom, an aryloxy group, an alkyl group
- R 1 and R 2 together represent an alkylene group having 3 to 5 carbon atoms
- R 3 is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a cycloalkyl group having 5 to 7 carbon atoms, a hydroxyalkyl group having 1 to 3 carbon atoms, a benzyl group, a naphthyl group, a phenol group, or 1 carbon atom.
- the wrinkle is dermatosis.
- the wrinkle is atopic dermatitis.
- hemorrhoids are dermatitis, urticaria, eczema, urticaria, insect bites, hay caused by hay fever or food allergy; jaundice associated with jaundice; kidney disease, diabetes, collagen disease or malignant tumor Acupuncture as a complication; or acupuncture caused by heat and cold stimulation.
- the pyrazolone derivative represented by the formula (I) is 3-methyl 1-phenol 2-virazolin-5-one.
- a medicament for treatment and Z or prevention of cutaneous pruritus which contains 3-methyl-1-phenyl-2-pyrazolin-5-one as an active ingredient.
- a medicament for treatment and Z or prevention of atopic dermatitis comprising 3-methyl 1-phenol 1-2 pyrazoline 5-one as an active ingredient Is done.
- a pyrazolone derivative represented by the above formula (I) or a physiologically acceptable salt thereof, or a hydrate or solvate thereof as an active ingredient, A glaze is provided.
- treatment and z or prevention of a pyrazolone derivative represented by the above formula (I) or a physiologically acceptable salt thereof, or a hydrate or solvate thereof is provided.
- a method of treating and / or preventing epilepsy comprising administering an effective amount to a mammal, including a human.
- treatment and z or prevention of a pyrazolone derivative represented by the above formula (I) or a physiologically acceptable salt thereof, or a hydrate or solvate thereof comprising the step of administering an effective amount to mammals including humans.
- a method for treating dermatosis comprising the step of administering a therapeutic and Z or prophylactically effective amount of 3-methyl-1 feniloo 2 pyrazolin-5-one to mammals including humans. Methods of treatment and Z or prevention are provided.
- the treatment and treatment of atopic dermatitis comprising the steps of administering 3 methyl 1-phenyl-2-pyrazolin 1 5one and administering Z or a prophylactically effective amount to a mammal, including a human.
- Z or methods of prevention are provided.
- a pyrazolone derivative represented by the formula (I) or a physiologically acceptable salt thereof for the manufacture of a medicament for the treatment and Z or prevention of epilepsy, or Use of such hydrates or solvates is provided.
- a virazolone derivative represented by formula (I) or a physiologically acceptable salt thereof, or a hydrate or solution thereof for the production of an antidepressant Use of a solvate is provided.
- compositions for treatment and Z or prevention of wrinkles including dermatoses and atopic dermatitis, etc.
- anti-epileptic agents in the present specification, these are collectively referred to as May be abbreviated as the pharmaceutical of the invention
- the compound represented by the formula (I) used in the present invention may also have a structure represented by the following formula (1) or (1 ") due to tautomerism.
- a structure represented by the following formula (1) or (1 ) due to tautomerism.
- one of the tautomers is shown, but the existence of the following tautomers will be obvious to those skilled in the art:
- the following formula () or Compound represented by ( ⁇ ) or its physiology Use pharmaceutically acceptable salts, or hydrates or solvates thereof.
- the aryl group in the definition of R 1 may be either a monocyclic or polycyclic aryl group.
- a substituent such as a phenyl group or a naphthyl group, an alkyl group such as a methyl group or a butyl group, an alkoxy group such as a methoxy group or a butoxy group, a halogen atom such as a chlorine atom, or a substituent such as a hydroxyl group.
- a phenol group a same applies to aryl moieties in other substituents having aryl moieties (such as aryloxy groups).
- the alkyl group having 1 to 5 carbon atoms in the definition of R 2 and R 3 may be either linear or branched. Examples thereof include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, and a pentyl group. The same applies to the alkyl moiety in other substituents having an alkyl moiety (alkoxycarboalkyl group).
- the alkylene group having 3 to 5 carbon atoms in the definition of R 1 and R 2 includes trimethylene group, tetramethylene group, pentamethylene group, methyltrimethylene group, etyltrimethylene group, dimethyltrimethylene group, methyltetramethylene group. A methylene group etc. are mentioned.
- the aryloxy group in the definition of R 2 includes p-methylphenoxy group, p-methoxyphenoxy group, p-chlorophenoxy group, p-hydroxyphenoxy group, and the like.
- mercercapto group p-methylphenol mercapto group, p-methoxyphenylmercapto group, p-chlorophenol mercapto group, p-hydroxyphenol- Examples include a rumercapto group.
- Examples of the hydroxyalkyl group having 1 to 3 carbon atoms in the definition of R 2 and R 3, hydroxy methylation group, 2-hydroxy E chill groups include 3-hydroxypropyl group and the like.
- Examples of the cycloalkyl group having 5 to 7 carbon atoms in the definition of R 3 include a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group.
- the alkoxy group having 1 to 5 carbon atoms in the substituent of the phenyl group includes methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, pentyloxy group and the like.
- Examples of the alkoxycarbon group having 2 to 5 carbon atoms in total include methoxycarbol group, ethoxycarbol group, propoxycarbol group, butoxycarboro group, etc.
- Examples of the alkyl mercapto group of 3 include a methyl mercapto group, an ethyl mercapto group, and a propyl mercapto group.
- the dialkylamino group having 2 to 8 carbon atoms are dimethylamino group, jetylamino group, dipropylamino group, dibutylamino group. Roh group, and the like.
- Examples of the compound (I) suitably used as the active ingredient of the medicament of the present invention include the compounds shown below.
- a physiologically acceptable salt may be used in addition to the free form compound represented by the formula (I).
- Physiologically acceptable salts include salts with mineral acids such as hydrochloric acid, sulfuric acid, hydrobromide, phosphoric acid; methanesulfonic acid, p-toluenesulfonic acid, acetic acid, oxalic acid, citrate, malic acid, Salts with organic acids such as fumaric acid; Salts with alkali metals such as sodium and potassium; Salts with alkaline earth metals such as magnesium; Amines such as ammonia, ethanolamine, 2-amino-2-methyl 1 propanol, etc. Salt.
- the type of salt is not particularly limited as long as it is physiologically acceptable.
- the dose of the medicament of the present invention is not particularly limited, but is usually 0.1 to 100 mg / kg body weight per day in the case of oral administration in general as the weight of the compound represented by formula (I) which is an active ingredient. In the case of parenteral administration, it is 0.1 to 100 mg / kg body weight per day.
- the above dose may be increased or decreased as appropriate according to the age, pathologic condition and symptoms that it is preferable to administer once a day or divided into 2 to 3 times a day.
- the compound represented by the above formula (I) or a physiologically acceptable salt thereof, or a hydrate or solvate thereof may be administered as it is.
- a pharmaceutical composition containing the above-mentioned substance as an active ingredient and a pharmacologically and pharmaceutically acceptable additive.
- Examples of pharmacologically and pharmaceutically acceptable additives include excipients, disintegrants or disintegration aids, binders, lubricants, coating agents, dyes, diluents, and bases. , Solubilizers or solubilizers, tonicity agents, pH regulators, stabilizers, propellants, and adhesives can be used.
- compositions suitable for oral administration include, for example, glucose, lactose, D— Excipients such as mannitol, starch, or crystalline cellulose; disintegrants or disintegration aids such as carboxymethyl cellulose, starch, or carboxymethylcellulose calcium; hydroxypropylcellulose, hydroxypropylmethylcellulose, polybulur pyrrolidone, or Binders such as gelatin; lubricants such as magnesium stearate or talc; coating agents such as hydroxypropylmethylcellulose, sucrose, polyethylene glycol or titanium oxide; petrolatum, liquid paraffin, polyethylene glycol, gelatin, kaolin, glycerin, purified water Alternatively, a base such as hard fat can be used.
- Excipients such as mannitol, starch, or crystalline cellulose
- disintegrants or disintegration aids such as carboxymethyl cellulose, starch, or carboxymethylcellulose calcium
- compositions suitable for injection or infusion include solubilizers or solubilizers that can constitute aqueous or use-soluble injections such as distilled water for injection, physiological saline, and propylene glycol; glucose; It is possible to use additives such as isotonic agents such as sodium chloride, sodium chloride, D-mannitol and glycerin; pH regulators such as inorganic acids, organic acids, inorganic bases and organic bases.
- the pharmaceutical form of the present invention is not particularly limited, and can take various forms that can be used by those skilled in the art.
- pharmaceuticals suitable for oral administration for example, tablets, capsules, powders, fine granules, granules and the like can be prepared using solid pharmaceutical additives, and liquid pharmaceutical additives can be used. Syrups and the like can be prepared.
- injections, infusions, suppositories, transdermal absorption agents, and the like can be prepared as pharmaceuticals suitable for parenteral administration.
- the brain protective agent (instillation) containing the compound of formula (I) above as an active ingredient has already been used in clinical practice (generic name “Edaravone”, product name “Radicut”: The above-mentioned commercially available preparation can be used as it is in the pharmaceutical of the present invention manufactured and sold by Mitsubishi Welpharma Co., Ltd.
- the administration route of the medicament of the present invention is not particularly limited, and can be administered orally or parenterally.
- the administration route for parenteral administration is not particularly limited, and can be administered intravenously or intraarterially.
- the medicament of the present invention can be administered for the purpose of prevention, that is, prior to the onset of epilepsy to a patient who has not developed epilepsy.
- the medicament of the present invention may be administered to the patient for the purpose of treatment, that is, prevention of worsening of symptoms, prevention of seizures, reduction of symptoms, healing of symptoms, etc. it can.
- Acupuncture to be administered with the medicament of the present invention is interpreted in the broadest sense. Wrinkles include all the unpleasant sensations that make you want to rub or rub the skin, and include wrinkles that occur on the skin and mucous membranes and cornea.
- dermatosis for example, when the skin is itchy with no visible skin symptoms; including senile dermatosis); dermatitis (atopic dermatitis, contact skin ), Urticaria, eczema, urticaria, insect bites, hay fever or food allergies (preferably dermatitis, urticaria, eczema moth); jaundice-related moths; kidney disease, diabetes, Examples include, but are not limited to, hemorrhoids as complications such as collagen disease or malignant tumors; and hemorrhoids caused by heat and cold stimulation.
- the medicament of the present invention can be used for the treatment and Z or prevention of hemorrhoids as described above, and at the same time, it can also be used as an anti-epileptic agent for suppressing hemorrhoids as described above.
- Test example V test using animal experimental model
- the weighed edaravone was completely dissolved with a small amount of IN NaOH, then neutralized with HC1 to pH 7.2 to 7.6, and the solution made up with physiological saline was used as an injection solution.
- mice Nine BALB / c mice per group were used. Mice previously anti tri - Torofue - Le a (TNP) monoclonal I g E 10 /zg/0.3mL sensitized by intravenous administration. 24 hours after the sensitization, an antigen solution (acetone Z olive oil (3: 1) containing 0.75% dinitrofluorobenzene (DNFB)) was applied to both sides of the right auricle in 5 L. Edaravone was administered intravenously at 10 mL / kg twice before the antigen application and 30 minutes after the antigen application.
- TNP tri - Torofue - Le a
- mice were acclimated in advance and placed in a glass container for observation (18cm in diameter X 20cm in height), and then 30 minutes of behavior in an unattended environment. I took a video camera. Later, from this video reproduction, the number of wrinkling actions for 30 minutes was counted and evaluated. In addition, the mouse's groining action was one pulling action for 1 second or more around the right auricle or around the right auricle with the hind paw, excluding grooming with the front paws (grooming).
- Table 1 shows the results of measurement of the number of droughts during 30 minutes.
- Intravenous administration of edaravone suppressed IgE-dependent (allergic) behavior in a dose-dependent manner and was significant at doses of 1 mg / kg and higher. In the state observation, no calming or somnolence such as that caused by drug administration was observed.
- Table 2 shows the results of evaluating the amount of immediate edema.
- Edaravone significantly suppressed the immediate skin edema response observed at the same time as wrinkle behavior at a dose of lmg / kg.
- Intravenous administration of edaravone showed a dose-dependent and significant suppression effect on wrinkles.
- the immediate edema response was confirmed to be suppressed at a dose of lmg / kg.
- This edema-suppressing action is thought to have been produced by a mechanism different from that of the wrinkle-suppressing action.
- the BALB / c mice used in the experiment have little involvement of histamine in sputum, but the immediate edema response of the skin (increased vascular permeability) observed simultaneously with sputum behavior involves mast cell degranulation and histamine. It is said that there is. Therefore, edaravone may suppress the edema response of the skin by a mechanism mediated by histamine including degranulation of mast cells, in addition to the effect of suppressing wrinkles by a mechanism not mediated by histamine.
- the medicament according to the present invention can effectively treat and prevent epilepsy.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-352502 | 2004-12-06 | ||
JP2004352502A JP2008037753A (ja) | 2004-12-06 | 2004-12-06 | 掻痒の治療及び/又は予防剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006062097A1 true WO2006062097A1 (ja) | 2006-06-15 |
Family
ID=36577924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/022372 WO2006062097A1 (ja) | 2004-12-06 | 2005-12-06 | 掻痒の治療及び/又は予防剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2008037753A (ja) |
WO (1) | WO2006062097A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018164443A1 (ko) * | 2017-03-06 | 2018-09-13 | 서울대학교 산학협력단 | 피라졸 유도체를 유효성분으로 함유하는 소양증의 예방 또는 치료용 약학적 조성물 및 이를 검출하기 위한 스크리닝 방법 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5591720B2 (ja) | 2009-01-29 | 2014-09-17 | 株式会社林原 | 抗神経変性疾患剤 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09501925A (ja) * | 1993-08-27 | 1997-02-25 | バイヤースドルフ・アクチエンゲゼルシヤフト | 感受性が高い、過剰反応性の、そして低活性の皮膚状態、アクネの形態、アトピー性皮膚炎、乾癬、痒疹、光線皮膚病、魚鱗癬及びウイルス感染症に対する物質類 |
JPH10279480A (ja) * | 1997-04-07 | 1998-10-20 | Mitsubishi Chem Corp | 皮膚組織障害の予防・治療剤 |
JP2004099486A (ja) * | 2002-09-06 | 2004-04-02 | Mikasa Seiyaku Co Ltd | フリーラジカル性疾患用外用剤 |
-
2004
- 2004-12-06 JP JP2004352502A patent/JP2008037753A/ja active Pending
-
2005
- 2005-12-06 WO PCT/JP2005/022372 patent/WO2006062097A1/ja not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09501925A (ja) * | 1993-08-27 | 1997-02-25 | バイヤースドルフ・アクチエンゲゼルシヤフト | 感受性が高い、過剰反応性の、そして低活性の皮膚状態、アクネの形態、アトピー性皮膚炎、乾癬、痒疹、光線皮膚病、魚鱗癬及びウイルス感染症に対する物質類 |
JPH10279480A (ja) * | 1997-04-07 | 1998-10-20 | Mitsubishi Chem Corp | 皮膚組織障害の予防・治療剤 |
JP2004099486A (ja) * | 2002-09-06 | 2004-04-02 | Mikasa Seiyaku Co Ltd | フリーラジカル性疾患用外用剤 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018164443A1 (ko) * | 2017-03-06 | 2018-09-13 | 서울대학교 산학협력단 | 피라졸 유도체를 유효성분으로 함유하는 소양증의 예방 또는 치료용 약학적 조성물 및 이를 검출하기 위한 스크리닝 방법 |
US11311514B2 (en) | 2017-03-06 | 2022-04-26 | Seoul National University R&Db Foundation | Pharmaceutical composition for preventing or treating pruritus, containing pyrazole derivative as active ingredient, and screening method for detecting same |
Also Published As
Publication number | Publication date |
---|---|
JP2008037753A (ja) | 2008-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017189613A1 (en) | Methods of using fasn inhibitors | |
WO2024060911A1 (zh) | 苯并异噻唑化合物及其药物组合物和应用 | |
JP2010043132A (ja) | 抗血栓薬とピラゾロン誘導体との組み合わせ薬剤 | |
JP6860677B2 (ja) | グローコカリキシンa誘導体、その医薬的に許容できる塩または医薬組成物、およびこれらの乾癬治療用医薬の調製における使用 | |
JP2022017516A (ja) | Hiv-1プロテアーゼ阻害剤およびその使用 | |
WO2006062097A1 (ja) | 掻痒の治療及び/又は予防剤 | |
US20070004777A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
JP5469707B2 (ja) | 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物 | |
JP5259970B2 (ja) | 薬物依存症治療剤 | |
CA3039070A1 (en) | Inhibitors of mtor-deptor interactions and methods of use thereof | |
JP2004123716A (ja) | 化学物質に起因する肝障害の予防及び/又は治療のための医薬 | |
JP2005029573A (ja) | 腫瘍転移抑制剤 | |
JPWO2004022543A1 (ja) | 炎症性腸疾患の予防及び/又は治療のための医薬 | |
JPWO2006126625A1 (ja) | ピラゾロン誘導体を含む医薬 | |
WO2007018226A1 (ja) | 角膜障害の予防及び/又は治療剤 | |
JP2004002381A (ja) | エンドトキシン血症に起因する肝障害の予防及び/又は治療のための医薬 | |
JP2004277315A (ja) | 抗腫瘍剤 | |
JPWO2004063167A1 (ja) | 血液脳関門破綻抑制剤 | |
JP2006096664A (ja) | 肝繊維化抑制剤 | |
JP2004115508A (ja) | 熱傷皮膚組織の機能改善のための医薬 | |
JP2003267871A (ja) | 放射線障害予防剤 | |
JP2004002400A (ja) | 軽微低体温療法を行うために用いる脳保護及び/又は脳機能正常化のための医薬 | |
JP2004123700A (ja) | パーオキシナイトライト消去剤 | |
WO2003078401A1 (fr) | Agent prophylactique et/ou therapeutique conçu pour un trouble cerebral ischemique hypoxique | |
JP2004161720A (ja) | パラコート中毒の治療・予防剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05814495 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |